Sanofi PE Ratio 2010-2024 | SNY
Current and historical p/e ratio for Sanofi (SNY) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Sanofi PE ratio as of December 20, 2024 is 10.92.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Sanofi PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-12-20 |
47.71 |
|
24.34 |
| 2024-09-30 |
57.63 |
$1.96 |
29.40 |
| 2024-06-30 |
48.52 |
$1.84 |
26.37 |
| 2024-03-31 |
46.65 |
$1.99 |
23.44 |
| 2023-12-31 |
47.73 |
$2.36 |
20.23 |
| 2023-09-30 |
51.49 |
$3.19 |
16.14 |
| 2023-06-30 |
51.74 |
$2.98 |
17.36 |
| 2023-03-31 |
50.34 |
$3.44 |
14.63 |
| 2022-12-31 |
44.80 |
$2.58 |
17.36 |
| 2022-03-31 |
45.96 |
$2.74 |
16.77 |
| 2021-09-30 |
43.16 |
$2.75 |
15.69 |
| 2021-06-30 |
47.14 |
$2.40 |
19.64 |
| 2021-03-31 |
42.66 |
$3.23 |
13.21 |
| 2020-09-30 |
43.27 |
$3.00 |
14.42 |
| 2020-03-31 |
36.39 |
$2.59 |
14.05 |
| 2019-09-30 |
38.56 |
$1.91 |
20.19 |
| 2019-03-31 |
35.37 |
$1.81 |
19.54 |
| 2018-03-31 |
30.56 |
$1.74 |
17.57 |
| 2017-12-31 |
32.79 |
$3.65 |
8.98 |
| 2017-09-30 |
37.97 |
$3.92 |
9.69 |
| 2017-06-30 |
36.53 |
$3.92 |
9.32 |
| 2017-03-31 |
33.37 |
$3.98 |
8.39 |
| 2016-12-31 |
29.83 |
$2.04 |
14.62 |
| 2016-09-30 |
28.17 |
$2.40 |
11.74 |
| 2016-06-30 |
30.87 |
$2.22 |
13.90 |
| 2016-03-31 |
28.41 |
$2.05 |
13.86 |
| 2015-09-30 |
33.58 |
$1.80 |
18.66 |
| 2015-06-30 |
35.04 |
$1.61 |
21.76 |
| 2014-06-30 |
36.43 |
$1.60 |
22.77 |
| 2013-06-30 |
34.07 |
$2.17 |
15.70 |
| 2022-06-30 |
46.28 |
$2.66 |
17.40 |
| 2012-06-30 |
24.14 |
$3.21 |
7.52 |
| 2012-03-31 |
23.66 |
$3.23 |
7.32 |
| 2011-12-31 |
22.31 |
$3.54 |
6.30 |
| 2011-09-30 |
20.02 |
$3.05 |
6.57 |
| 2011-06-30 |
24.52 |
$2.85 |
8.61 |
| 2011-03-31 |
20.78 |
$3.14 |
6.62 |
| 2010-12-31 |
19.02 |
$3.15 |
6.04 |
| 2010-09-30 |
19.62 |
$3.56 |
5.51 |
| 2010-06-30 |
17.74 |
$3.97 |
4.47 |
| 2010-03-31 |
21.27 |
$4.36 |
4.88 |
| 2009-12-31 |
22.35 |
$4.21 |
5.31 |
| 2009-09-30 |
21.03 |
$4.42 |
4.76 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$120.547B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
